Thrombolysis beyond 4.5 h in Acute Ischemic Stroke.
Mark R EthertonRajan R GadhiaLee H SchwammPublished in: Current neurology and neuroscience reports (2020)
In recent years, several randomized, placebo-controlled trials have shown neuroimaging-guided approaches to be feasible in determining eligibility for alteplase beyond 4.5 h from last known well, and efficacious for reducing disability. DWI-FLAIR mismatch on MRI is an effective tool to identify stroke lesions less than 4.5 h in onset in patients with stroke of unknown symptom onset. Additionally, an automated perfusion-based approach, assessing for a disproportionate amount of salvageable tissue, is effective in identifying patients likely to benefit from late window alteplase treatment. In patients with stroke of unknown symptom onset, an individualized approach using neuroimaging to determine time of stroke onset or presence of salvageable brain tissue is feasible in the acute setting and associated with improved long-term outcomes.
Keyphrases
- atrial fibrillation
- placebo controlled
- end stage renal disease
- double blind
- acute ischemic stroke
- newly diagnosed
- magnetic resonance imaging
- contrast enhanced
- cerebral ischemia
- chronic kidney disease
- pulmonary embolism
- peritoneal dialysis
- prognostic factors
- multiple sclerosis
- patient reported
- squamous cell carcinoma
- open label
- liver failure
- computed tomography
- radiation therapy
- intensive care unit
- study protocol
- diffusion weighted
- drug induced
- subarachnoid hemorrhage
- extracorporeal membrane oxygenation
- combination therapy
- phase ii study